BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021

In RATIONALE 309, tislelizumab in combination with chemotherapy significantly prolonged progression-free survival for patients, with survival benefit observed across patient subgroups The safety

Related Keywords

China ,Japan ,United States ,Canada ,Brazil ,Chinese ,Brazilian ,America ,Yunpeng Yang ,Gabrielle Zhou ,Yong Ben ,Amgen ,Oncology Esmoio Congress ,Drug Administration ,Professor At Sun Yat Sen University Cancer Center ,Novartis ,Exchange Commission ,Tislelizumab Clinical Program ,China National Medical Products Administration ,European Society For Medical Oncology Immuno ,Bristol Myers Squibb ,European Society ,Medical Oncology Immuno ,Chief Medical Officer ,Drug Evaluation ,Biologics License Application ,Sun Yat Sen University Cancer Center ,About Nasopharyngeal ,Biologics License Applications ,North America ,Tislelizumab Clinical ,Hodgkin Lymphoma ,Mirati Therapeutics ,Private Securities Litigation Reform Act ,Cancer Biology ,Access July ,Therapeutic Medicine ,Causes Control ,Targets Ther ,Pacific Journal ,Cancer Prevention ,Metastatic Patterns ,Metastatic Nasopharyngeal Carcinoma ,Beigene ,Presents ,Results ,Rom ,Hase ,Trial ,Tislelizumab ,Nasopharyngeal ,Dancer ,Osmo ,Immuno ,Ncology ,Congress ,021 ,